» Articles » PMID: 39312096

Zhumeria Majdae Essential Oil Attenuates TNBS-induced Colitis in Rats by Regulating Inflammatory and Apoptotic Pathways

Overview
Specialty Pharmacology
Date 2024 Sep 23
PMID 39312096
Authors
Affiliations
Soon will be listed here.
Abstract

Background And Aim: Zhumeria majdae, a unique native plant of southern Iran, has been traditionally used to treat various health issues. Preclinical studies suggest its therapeutic potential for immunological and inflammatory disorders. This study investigates the effect of Z. majdae essential oil (ZMEO) on TNBS-induced colitis in rats, focusing on the NF-κB/p38 MAPK/Nrf-2 pathway.

Experimental Procedure: Forty-eight male Wistar rats were used, with all groups except the sham group receiving a single intra-rectal dose of TNBS. Three different doses of ZMEO and also 1 mg/kg dexamethasone were administered orally for 2 weeks. Colon tissue was analyzed for ulcer index, histological changes, inflammatory cytokines, apoptotic factors, and levels of NF-κB, p38 MAPK, and Nrf-2.

Key Results: GC-mass analysis identified 25 compounds with linalool (52.01%) and camphor (31.01%) as the major compounds in ZMEO. ZMEO ameliorated colon injuries, reduced ulcer index, and prevented the elevation of pro-inflammatory cytokines and pro-apoptotic proteins. It also increased the levels of IL-10 and Bcl-2 proteins. Furthermore, ZMEO decreased the expression of p-NF-κB and p38 MAPK while increasing the expression of pNrf-2.

Conclusions: ZMEO mitigates colon damage associated with IBD by suppressing inflammatory cytokines and pro-apoptotic proteins possibly through modulating the NF-κB/p38 MAPK/Nrf-2 signaling pathway.

References
1.
Acar Y, Agagunduz D, De Cicco P, Capasso R . Flavonoids: Their putative neurologic roles, epigenetic changes, and gut microbiota alterations in Parkinson's disease. Biomed Pharmacother. 2023; 168:115788. DOI: 10.1016/j.biopha.2023.115788. View

2.
Agagunduz D, Gencer Bingol F, Celik E, Cemali O, Ozenir C, Ozogul F . Recent developments in the probiotics as live biotherapeutic products (LBPs) as modulators of gut brain axis related neurological conditions. J Transl Med. 2022; 20(1):460. PMC: 9548122. DOI: 10.1186/s12967-022-03609-y. View

3.
Agagunduz D, Celik E, Cemali O, Gencer Bingol F, Ozenir C, Ozogul F . Probiotics, Live Biotherapeutic Products (LBPs), and Gut-Brain Axis Related Psychological Conditions: Implications for Research and Dietetics. Probiotics Antimicrob Proteins. 2023; 15(4):1014-1031. DOI: 10.1007/s12602-023-10092-4. View

4.
Agagunduz D, Cocozza E, Cemali O, Bayazit A, Nani M, Cerqua I . Understanding the role of the gut microbiome in gastrointestinal cancer: A review. Front Pharmacol. 2023; 14:1130562. PMC: 9903080. DOI: 10.3389/fphar.2023.1130562. View

5.
Agagunduz D, Icer M, Yesildemir O, Kocak T, Kocyigit E, Capasso R . The roles of dietary lipids and lipidomics in gut-brain axis in type 2 diabetes mellitus. J Transl Med. 2023; 21(1):240. PMC: 10068184. DOI: 10.1186/s12967-023-04088-5. View